
Beat YoY growth, but sequential PAT decline signals momentum loss
specialty mix ARPOB · Raipur unprofitable · sequential decline

specialty mix ARPOB · Raipur unprofitable · sequential decline

earnings · transformation · CDMO

CDMO · Formulation launches · Biologics scaling

CDMO · Jammu facility · volume growth

volume growth · CDMO demand · Jammu ramp

FDA remediation · leverage drag · Pharma CDMO

FDA remediation · Animal Health scaling · CDMO partnerships

pricing power · volume miss · capacity ramp

pricing power · capacity ramp-up · volume miss

HCG · oncology · ARPP stagnation

payor mix · EBITDA margin expansion · volume growth

diagnostics · capex expansion · tier-2

network expansion · margin resilience · B2C leverage

revenue growth · margin recovery · battery materials

PFN 31% growth · battery materials · greenfield Q3

CDMO · ADC · oligonucleotides

NJ Bio drag · Phase 3 conversions · Sapala growth

margin compression · new unit ramp · PAT cliff

new unit ramp · margin pressure · debt reduction

merger-integration · synergies-pending · margin-compression

merger-integration · synergies-pending · margin-compression

diabetes franchise · public sector expansion · partnership drag

diabetes leadership · public sector expansion · partnership volatility

margin compression · Noida ramp-up · greenfield execution

volume growth · Noida ramp-up · margin compression

integrated care model · margin compression · insurance losses

integrated care model · margin expansion · insurance losses

margin compression · PAT growth lag · ESOP charge

ESOP alignment · new unit ramp-up · oncology pricing headwind

portfolio transformation · innovation 7% · Shingrix 65%